SAFETY AND EFFICACY OF BRL49653C THERAPY IN NIDDM

$16,342M01FY2000RRNIH

University Of Tennessee Health Sci Ctr, Memphis TN

Investigators

Linked publications & trials

Paper 38474830 Paper 34369105 Paper 32014493 Paper 31898874 Paper 31732174 Paper 29911741 Paper 29333295 Paper 29216357 Paper 28222422 Paper 26706699 Paper 26116207 Paper 25887362 Paper 25133996 Paper 25127483 Paper 25111807 Paper 24857973 Paper 24641885 Paper 24628558 Paper 24065013 Paper 23709655 Paper 23553666 Paper 23359362 Paper 23307503 Paper 23140075 Paper 23118422 Paper 22766890 Paper 22455415 Paper 22264468 Paper 22182286 Paper 22138077 Paper 22064686 Paper 21828345 Paper 21714923 Paper 21466619 Paper 21462727 Paper 21292809 Paper 21134520 Paper 21062906 Paper 20680035 Paper 20639793 Paper 20634323 Paper 20525373 Paper 20484473 Paper 20422396 Paper 20357497 Paper 20338738 Paper 20129018 Paper 19922431 Paper 19851297 Paper 19638215 Paper 19631042 Paper 19593725 Paper 19526254 Paper 19487639 Paper 19478457 Paper 19464027 Paper 19461553 Paper 19276238 Paper 19232000 Paper 19155752 Paper 18957954 Paper 18713189 Paper 18687759 Paper 18663318 Paper 18512816 Paper 18502255 Paper 18437445 Paper 18375417 Paper 18280838 Paper 18277834 Paper 18272841 Paper 18270259 Paper 18267303 Paper 18227843 Paper 18212812 Paper 18212657 Paper 18191071 Paper 18172551 Paper 18046181 Paper 18004714 Paper 17943324 Paper 17852540 Paper 17667841 Paper 17644623 Paper 17599861 Paper 17525715 Paper 17495451 Paper 17495450 Paper 17418236 Paper 17410445 Paper 17343705 Paper 17342176 Paper 17100755 Paper 17094096 Paper 17060218 Paper 16967634 Paper 16855197 Paper 16855180 Paper 16845234 Paper 16652430

Abstract

This study is to evaluate the efficacy of BRL 49653c in reducing hyperglycemia when administered to NIDDM patients, as assessed by a reduction in HbAe1c after 16 weeks of repetitive, oral dosing, at a dose of 4 mg or 8 mg once daily in comparison to placebo."

View original record on NIH RePORTER →